Edition:
United Kingdom

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

7.65USD
16 Feb 2018
Change (% chg)

$0.43 (+5.88%)
Prev Close
$7.22
Open
$7.20
Day's High
$7.65
Day's Low
$7.20
Volume
24,155
Avg. Vol
18,010
52-wk High
$7.90
52-wk Low
$3.35

Chart for

About

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads... (more)

Overall

Beta: -0.59
Market Cap(Mil.): $173.02
Shares Outstanding(Mil.): 28.13
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 148.59 16.64
EPS (TTM): -- -- --
ROI: -- 9.38 10.66
ROE: -- 14.72 14.30

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

15 Feb 2018

BRIEF-Cytosorbents Sees Q4 2017 Revenue About $4.6 Million

* CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER

08 Jan 2018

BRIEF-U.S. FDA Approves Cytosorbents' Refresh 2 IDE Application With Conditions

* CYTOSORBENTS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE U.S. REFRESH 2 PIVOTAL CARDIAC SURGERY TRIAL IDE APPLICATION

21 Dec 2017

BRIEF-Cytosorbents posts Q3 revenue of $3.8 mln

* Cytosorbents continues strong trajectory of growth in the third quarter 2017

09 Nov 2017

Competitors

Earnings vs. Estimates